Posted by Michael Wonder on 06 Jan 2021
MorphoSys and Incyte announce the acceptance of the Swissmedic marketing authorisation application for tafasitamab
5 January 2021 - The Swissmedic marketing authorisation application seeks approval for tafasitamab in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
MorphoSys and Incyte today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has accepted the marketing authorisation application for tafasitamab, a humanised Fc modified cytolytic CD19 targeting monoclonal antibody.
